Loading…
Louisiana State University Health Science Center's IRB failed to conduct continuing review of drug research studies at the required intervals of not less than once per year, in violation of 21 CFR 56.109(f). The inspection conducted between July 17-26, 2023, identified that the IRB did not adhere to applicable statutory requirements of the FD&C Act and FDA regulations governing the protection of human subjects in clinical investigations. This violation was part of the FDA's Bioresearch Monitoring Program designed to ensure the rights, safety, and welfare of human research subjects were adequately protected.